First recognized in 1991 and finally termed such in 2007, "mast cell activation syndrome" (MCAS) is a large, likely quite prevalent collection of illnesses resulting from MCs which have been inappropriately activated but which, in contrast to the rare "mastocytosis," are not proliferating, or otherwise accumulating, to any significant extent. Due to the marked diversity of direct and indirect, local and remote biological effects caused by the plethora of mediators released by MCs, MCAS typically presents as chronic, persistent or recurrent, waxing and waning or slowly progressive multisystem polymorbidity generally, but not necessarily, of an inflammatory theme. Suspected to be of clonal origin in most cases, MCAS usually is acquired relatively early in life via unknown mechanisms; interaction of environmental factors with inheritable risk factors is one possibility. Initial manifestations often occur in childhood or adolescence but are non-specific; in fact, virtually all of the syndrome's manifestations are non-specific, leading to decades of mysterious illness (and incorrect diagnoses often poorly responsive to empiric therapies) prior to diagnosis. A large menagerie of mutations in MC regulatory elements has been found in MCAS patients; most patients appear to have multiple such mutations, with no clear patterns, or genotype-phenotype correlations, yet apparent. Such mutational heterogeneity likely drives the heterogeneity of aberrant MC mediator expression, in turn causing the extreme heterogeneity of clinical presentation. Different MCAS patients can present with polar opposite clinical aberrancies. All of the body's systems can be affected by MCAS. In addition to clinical heterogeneity, diagnosis is confounded by difficulty not only in detecting sensitive and specific biomarkers of primary MC disease but also in finding histologic evidence of a non-proliferative disease wrought by cells capable of great pleomorphism. For example, in contrast to proliferative mastocytosis which usually drives significantly elevated tryptase levels, relatively non- proliferative MCAS usually presents with normal tryptase levels; instead, histamine, MCspecific prostaglandins, and other mediators need to be assessed in evaluations for MCAS. Although the World Health Organization 2008 classification scheme for myeloproliferative neoplasms does not recognize MCAS, proposals for diagnostic criteria have been published recently and generally require presence of symptoms consistent with chronic/recurrent aberrant MC mediator release, laboratory evidence of such release (or of mast cell proliferation not meeting WHO criteria for systemic mastocytosis), absence of any other evident disease which could better explain the full range of findings in the patient, and, ideally but not necessarily, at least partial response to therapy targeted against MCs or MC mediators. Systemic MC disease of any form is not presently curable. Therapies for MCAS generally aim to control and ameliorate the disease by inhibiting aberrant mediator production and release, blocking released mediators, and/or managing the consequences of aberrantly released mediators. Many such therapies are available. Although there presently is no method to predict which set of therapies will best control the individual patient's disease, a methodical, persistent, trial-and-error approach usually succeeds in finding significantly helpful therapy. Lifespan for most MCAS patients appears normal, but quality of life can be mildly to severely impaired absent correct diagnosis and effective treatment.
|Original language||English (US)|
|Title of host publication||Mast Cells|
|Subtitle of host publication||Phenotypic Features, Biological Functions and Role in Immunity|
|Publisher||Nova Science Publishers, Inc.|
|Number of pages||78|
|State||Published - Apr 1 2013|